Reify Health is a provider of leading cloud-based solutions that connect and empower the clinical trial ecosystem.
Reify Health develops cloud-based software that accelerates the development of new and life-saving therapies.
Reify Health was founded in 2010 by Ralph Passarella and Michael Lin. The company is headquartered in Boston, Massachusetts.
Reify has built a new foundation for how clinical trials are run through its business entities, StudyTeam and Care Access. StudyTeam helps clinical trial teams achieve faster, more predictable enrollment while eliminating the tedious work that saps productivity and study budget.
StudyTeam delivers the best-in-class technology platform for optimizing patient recruitment and enrollment, and is used by top-20 global biopharma companies such as Amgen, AstraZeneca, and Eli Lilly and Company, and approximately 4,000 research sites across 65 countries.
Reify's Care Access, having conducted the most advanced decentralized trials at scale, is the world’s leading decentralized research organization that brings clinical trial infrastructure directly to patients, healthcare providers, and communities.
Reify is backed by Coatue, ICONIQ Growth, Battery Ventures, Altimeter Capital, Adams Street Partners, Asset Management Ventures, Dragoneer Investment Group, Sierra Ventures, and others. The company raised $220M in Series D round on Apr 21, 2022. This brings Reify's total funding to $477.4M to date. The latest round more than doubled the company's valuation to $4.8B, up from the previous $2.2B gained after Series C round on Aug 2021.